

PTO 892 DEA/FCE 1994 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  NOTICE OF REFERENCES CITED	SERIAL NUMBER  09/427,873	Art Unit  1648	Attachment to Paper Number
			18

APPLICANT : Boyd, M. R.
-------------------------

U.S. PATENT DOCUMENTS
-----------------------

*	DOCUMENT NUMBER	DATE	NAME(S)	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS
--------------------------

*	DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS	PERTINENT DRW SPEC

OTHER REFERENCES (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
---

	Saunders, J., 1992 (July), "Non-nucleoside inhibitors of HIV reverse transcriptase: screening successes--clinical failures.", Drug Design Discovery 8(4):255-63.
	Öberg, B. and L. Vrang, 1990, "Screening for new agents", Eur. J. Clin. Microbiol. Infect. Dis. 9(7):466-471.
	Richman, D. D., 1996, "Antiretroviral drug resistance: mechanisms, pathogenesis, clinical significance.", Adv. Exp. Med. Biol. 394:383-95.
	Gait, M. J., and J. Karn, 1995, "Progress in anti-HIV structure-based drug design", TIBTECH 13:430-438.
	Ramachandran, R. V., et al., 1994, "Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons", J. Infect. Dis. 170:1009-13.
	Domingo, E., et al., 1985, "The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance-a review", Gene 40:1-8.
	Yarchoan, R., and S. Broder, 1992, "Correlations between the in vitro and in vivo activity of anti-HIV agents: implications for future drug development", J. Enzym. Inhibit. 6:99-111.

EXAMINER  Jeffrey S. Parkin, Ph.D.	DATE  02/08/03	* A COPY OF THIS REFERENCE IS NOT BEING FURNISHED WITH THIS OFFICE ACTION. (SEE MPEP SECTION 707.05(a)).  PAGE 1 OF 1
--	----------------------	---